tiprankstipranks
Takeda Pharmaceutical Co Ltd (TKPHF)
OTHER OTC:TKPHF

Takeda Pharmaceutical Co (TKPHF) Stock Price & Analysis

32 Followers

TKPHF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$23.80 - $33.48
Previous Close$27.25
Volume1.78K
Average Volume (3M)46.71K
Market Cap
$43.01B
Enterprise Value$70.76B
Total Cash (Recent Filing)¥457.80B
Total Debt (Recent Filing)¥4.84T
Price to Earnings (P/E)42.8
Beta0.31
Jul 31, 2024
Dividend Yield4.71%
Share Statistics
EPS (TTM)0.65
Shares Outstanding1,582,418,725
10 Day Avg. Volume81,768
30 Day Avg. Volume46,707
Standard Deviation0.07
R-Squared0.19
Alpha-0.00557
Financial Highlights & Ratios
Price to Book (P/B)-0.01
Price to Sales (P/S)0.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside26.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

Ownership Overview

0.00%4.58%8.46%86.96%
8.46% Other Institutional Investors
86.96% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

TKPHF FAQ

What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest stock price was $23.80 and its highest was $33.48 in the past 12 months.
    What is Takeda Pharmaceutical Co Ltd’s market cap?
    Currently, no data Available
    When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
    Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Jul 31, 2024 which is in 13 days.
      How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
      Takeda Pharmaceutical Co Ltd released its earnings results on May 09, 2024. The company reported -$0.013 earnings per share for the quarter, missing the consensus estimate of $0.007 by -$0.02.
        Is Takeda Pharmaceutical Co Ltd overvalued?
        According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Takeda Pharmaceutical Co Ltd pay dividends?
          Takeda Pharmaceutical Co Ltd pays a Annually dividend of $0.62 which represents an annual dividend yield of 4.71%. See more information on Takeda Pharmaceutical Co Ltd dividends here
            What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
            Takeda Pharmaceutical Co Ltd’s EPS estimate is $0.24.
              How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
              Takeda Pharmaceutical Co Ltd has 1,590,937,600 shares outstanding.
                What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
                Takeda Pharmaceutical Co Ltd reported an EPS of -$0.013 in its last earnings report, missing expectations of $0.007. Following the earnings report the stock price went up 5.051%.
                  Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
                  Currently, no hedge funds are holding shares in TKPHF
                  ---

                  Company Description

                  Takeda Pharmaceutical Co Ltd

                  Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
                  ---

                  TKPHF Company Deck

                  ---

                  TKPHF Earnings Call

                  Q4 2024
                  0:00 / 0:00
                  ---

                  TKPHF Stock 12 Month Forecast

                  Average Price Target

                  $35.32
                  ▲(26.70% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","36":"$36","27.75":"$27.8","30.5":"$30.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.324072,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$35.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$35.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.324072,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$35.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,27.75,30.5,33.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Feb<br/>2024","9":"May<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.25,26.948005538461537,27.646011076923077,28.344016615384614,29.042022153846155,29.74002769230769,30.438033230769232,31.13603876923077,31.83404430769231,32.532049846153846,33.23005538461538,33.92806092307693,34.626066461538464,{"y":35.324072,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.25,26.947692307692307,27.645384615384614,28.34307692307692,29.040769230769232,29.73846153846154,30.436153846153847,31.133846153846154,31.83153846153846,32.52923076923077,33.22692307692308,33.924615384615386,34.62230769230769,{"y":35.32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.25,26.948005538461537,27.646011076923077,28.344016615384614,29.042022153846155,29.74002769230769,30.438033230769232,31.13603876923077,31.83404430769231,32.532049846153846,33.23005538461538,33.92806092307693,34.626066461538464,{"y":35.324072,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.67,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.23,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.48,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.45,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.17,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.34,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.49,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.83,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.91,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.62,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.54,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.01,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.25,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Takeda Pharmaceutical Company
                  AstraZeneca
                  Sanofi
                  Novartis

                  Best Analysts Covering TKPHF

                  1 Year
                  1 Year Success Rate
                  1/2 ratings generated profit
                  50%
                  1 Year Average Return
                  -9.55%
                  reiterated a buy rating last month
                  Copying Stephen Barker's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -9.55% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis